catalYm

Immuno-oncology therapeutic

CatalYm is developing innovative immunotherapies targeting Growth Differentiation Factor 15 (GDF-15) to transform the tumor microenvironment and to substantially improve treatment options for patients with cancer.

By making tumors accessible and susceptible again for the patient‘s own immune system CatalYm has developed its approach to overcome major limitations of existing immunotherapies and to improve cancer patient survival and quality of life.